CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
N Chen, A Morello, Z Tano, PS Adusumilli - Oncoimmunology, 2017 - Taylor & Francis
N Chen, A Morello, Z Tano, PS Adusumilli
Oncoimmunology, 2017•Taylor & FrancisABSTRACT PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-
cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-
intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial
immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a
promising treatment approach for solid tumors.
cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-
intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial
immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a
promising treatment approach for solid tumors.
Abstract
PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a promising treatment approach for solid tumors.
Taylor & Francis Online